FDA

#Clinical trials #Drug development #EU #FDA #Regulatory

Regulatory affairs in 2023: Key trends and changes  

Dr Julie Warner is Vice President of Regulatory Affairs at global drug development consultancy, Boyds. In this article, she provides her expert insights into the key regulatory developments likely to shape the global drug development industry this year.    Implementation of the EU Clinical Trials Regulation  The way clinical trials (CTs)… Read More

#Business & Investment #Exclusive Content #Opinion #Regulatory #Trends & Analysis

Organ-on-a-chip
#Bioavailability #CN Bio #Collaboration #FDA #In vitro #Organ-on-a-chip

FDA expands organ-on-a-chip research collaboration

The US Food and Drug Administration (FDA) and CN Bio have expanded their collaboration for the second time, with new research aiming to evaluate multi-organ microphysiological systems (MPS) using the PhysioMimix Multi-organ System.   The system will initially be investigated for improving the preclinical estimation of human drug… Read More

#News

Lecanemab
#Alzheimer's #Biogen #Eisai #FDA #GlobalData #Monoclonal antibodies #United States

Uncertainty surrounds monoclonal antibody for Alzheimer’s

Leqembi’s prospects in the Alzheimer’s disease market remain uncertain despite its advantages over Aduhelm, says analytics company GlobalData.  Eisai and Biogen’s anti-amyloid beta (Aβ) monoclonal antibody (mAb), Leqembi (lecanemab), recently gained approval from the Food and Drug Administration (FDA) under the accelerated approval pathway for the treatment of Alzheimer’s disease… Read More

#News #Regulatory

Woman using an asthma inhaler
#Asthma #AstraZeneca #Avillion #FDA #Phase III trial #United States

FDA approves first rescue medication to manage asthma inflammation

Airsupra (albuterol/budesonide) has been approved in the US for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in people with asthma aged 18 years and older.  Airsupra is a pressurised metered-dose inhaler (pMDI), fixed-dose combination of albuterol, a short-acting beta2-agonist (SABA), and budesonide, an… Read More

#News #Regulatory

Pneumococcal disease vaccine
#Clinical trial #FDA #Immunology / Virology & Vaccines #Pneumonia #Regulatory #United States #Vaxcyte

Breakthrough Therapy designation for pneumococcal disease vaccine

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for VAX-24, Vaxcyte’s 24-valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease.  The decision was based on positive topline results from a Phase I/II proof-of-concept study, which evaluated the safety, tolerability and immunogenicity of VAX-24 in… Read More

#News #Regulatory

Uveal melanoma
#Cancer research #FDA #iOnctura #Ophthalmology #Orphan drugs #United States

FDA grants orphan drug status for uveal melanoma drug

The US Food and Drug Administration (FDA) has granted Orphan Drug Designation for iOnctura’s IOA-244, which is in development for solid and hematologic malignancies including uveal melanoma.  Uveal melanoma is a disease in which cancer originates in the tissues of the eye, causing symptoms such as blurred vision or a… Read More

#Cancer Research #News #Regulatory

Urinary system
#Bicycle Therapeutics #Cancer research #FDA #Oncology #United States

FDA fast-tracks metastatic urothelial cancer treatment

The United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to Bicycle Therapeutics’ BT8009 monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer.   BT8009 is a potential first in class Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a protein that… Read More

#Cancer Research #News #Regulatory #Trending News

#AI / data analytics / healthtech / informatics #Data management #Data standardisation #EMA #FDA #Regulatory #Trial data

Driving enhanced patient outcomes through data standardisation 

Greater data-centricity, supported by new technologies, is key to driving efficient product approvals and supply chains. Frits Stulp and Aida Demneri, partners at Deloitte (including Iperion – a Deloitte business), outline how life sciences companies can play their part in driving change. In the past two years, EU regulatory authorities… Read More

#Exclusive Content

US Food and Drug Administration
#Biologics / Biotechnology #Celltrion #Crohn's disease #FDA #Inflammatory Bowel Disease #Phase III trial #United States

First subcutaneous formulation of infliximab submitted to FDA

Celltrion USA has submitted a Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act for CT-P13 SC for the treatment of inflammatory bowel disease (IBD).  The submission is based on results from the Phase III pivotal data that evaluated the efficacy and safety of… Read More

#News #Regulatory

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

Podcast: Keep up-to-date on the latest industry news

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  The industry has seen breakthroughs announced in malaria treatment, epilepsy and major… Read More

#News

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

This week in drug discovery (28 November – 2 December)

News round-up for 28 November – 2 December by DDW Digital Content Editor Diana Spencer  The last seven days have seen breakthroughs announced in malaria treatment, epilepsy and major depressive disorders. The NHS in England has fast tracked another cancer drug, and, in Covid-19 news, researchers have… Read More

#News

Dystrophin muscle protein
#FDA #Gene therapy #Muscular dystrophy #Priority Review

Gene therapy granted FDA Priority Review

The US Food and Drug Administration (FDA) has accepted Sarepta Therapeutics’ Biologics License Application (BLA) seeking accelerated approval of SRP-9001 (delandistrogene moxeparvovec) for the treatment of ambulant individuals with Duchenne muscular dystrophy.   The therapy, which is being developed in partnership with Roche, has been granted Priority Review by the FDA,… Read More

#News #Regulatory

#Cancer research #Diabetes #Drug development #Drug discovery #FDA #Gene therapy #Haemophilia #MHRA #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders

News update available on DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  Gene therapies have made the headlines over the last week, with treatments… Read More

#News

#Cancer research #Diabetes #Drug development #Drug discovery #FDA #Gene therapy #Haemophilia #MHRA #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders

This week in drug discovery (21-25 November)

News round-up for 21-25 November by DDW Digital Content Editor Diana Spencer  Gene therapies have made the headlines over the last few days, with treatments for rare AADC deficiency, lung cancer and haemophilia B given the go ahead from regulators. This week has also seen the first… Read More

#News

#Cell and gene therapy #FDA #Gene therapy #Haemophilia #Regulatory

FDA approves first gene therapy for haemophilia B

The US Food and Drug Administration (FDA) has approved Hemgenix (etranacogene dezaparvovec-drlb), the first and only one-time gene therapy for appropriate adults with haemophilia B.   The drug is approved for the treatment of adults with haemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening… Read More

#News #Regulatory

Patient with type 1 diabetes
#Antibody #Diabetes #FDA #Type 1 diabetes #US

FDA approves first disease-modifying therapy for T1D

The US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for anti-CD3-directed antibody TZIELD (teplizumab-mzwv), the first immunomodulatory treatment for type 1 diabetes (T1D).   It is approved for intravenous use to delay the onset of stage 3 T1D in adult and paediatric patients aged eight years… Read More

#News #Regulatory